BioSpace News Archive

Olema Pharmaceuticals, Inc. announced the closing of its previously announced initial public offering of 12,650,000 shares of its common stock, which includes 1,650,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $19.00 per share.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that some of its management team members will be participating in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1 and 2, 2020.

Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. In connection with the offering,

TouchStar theta burst protocol leverages NeuroStar® Advanced Therapy’s patented Contact Sensing technology to help ensure the optimum prescribed treatment dose to patients

CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, President, Chief Executive Officer and Chair of the Board, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Primex, the leading provider of Internet of Medical Things (IoMT) environmental monitoring technologies, today announced its OneVue Sense™ temperature sensor and automated monitoring platform can help labs, pharmacies, hospitals, and other vaccine administrators across the healthcare industry prepare for the pending global rollout of COVID-19 vaccines.

The Pharmaceutical Research and Manufacturers of America named Debra DeShong as executive vice president of public affairs.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company’s presentation at the Piper Sandler 32 nd Annual Virtual Healthcare Conference. Adverum’s video webcast will be accessible on demand beginning today at 10:00 am ET under Events and Presentations in the Investors section of the company’s website. This webcast will

ATAI Life Sciences (“ATAI” or the “Company”), a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $125 million Series C financing round, including $32 million of its 2020 convertible debt that converted in connection with the Series C.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today has announced the acceptance and presentation details of two posters at the 2020 virtual annual meeting of the American Epilepsy Society (AES)